HaemoneticsSTU:HAZ -0.76%79 Days Payable is 30.53 as of Mar. 2026, which is 23% below its 10-year median of 39.88. GuruFocus rates STU:HAZ with a GF Score™ of 79/100 and a GF Value™ of €73.57. The stock has 4 warning signs investors should review. Among 795 Medical Devices & Instruments companies, Haemonetics ranks worse than 78.36% on this metric.
The historical rank and industry rank for Haemonetics's Days Payable or its related term are showing as below:
STU:HAZ'
s Days Payable Range Over the Past 10 Years
Min: 29.71 Med: 39.88 Max: 41.86
Current: 36.66
During the past 13 years, Haemonetics's highest Days Payable was 41.86. The lowest was 29.71. And the median was 39.88.
STU:HAZ's Days Payable is ranked worse than 78.36% of 795
companies
in the Medical Devices & Instruments industry
Industry Median: 68.07
vs STU:HAZ: 36.66
Haemonetics's Days Payable
declined
from Mar. 2025 (43.79) to Mar. 2026 (30.53).
It may suggest that Haemoneticsaccelerated paying its suppliers.
Haemonetics Days Payable Related Terms
Haemonetics Days Payable Historical Data
* Premium members only.
The historical data trend for Haemonetics's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:HAZ vs ITGR, IRTC, ESTA: Days Payable Comparison
For the Medical Devices subindustry, Haemonetics's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Haemonetics Days Payable vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Haemonetics's Days Payable distribution charts can be found below:
* The bar in red indicates where Haemonetics's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Haemonetics's Days Payable for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Haemonetics (STU:HAZ) has a Days Payable of 30.53 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Haemonetics and its competitors. This is 23% below median its historical median of 39.88. Over the past decade, Haemonetics' Days Payable has ranged from 29.71 to 41.86. According to the industry distribution chart, Haemonetics ranks #623 out of 795 companies in the Medical Devices & Instruments industry, placing it in the top 78.4%.
Is Haemonetics' Days Payable too high?
Haemonetics' current Days Payable of 30.53 is 23% below median its 10-year median of 39.88. Over the past 10 years, this metric has ranged from a low of 29.71 to a high of 41.86. The Medical Devices & Instruments industry median Days Payable is 68.07. Haemonetics' value of 30.53 is 55.1% below this industry median. Based on the distribution chart, Haemonetics ranks #623 out of 795 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Haemonetics has a GF Score™ of 79/100, reflecting its overall financial health beyond just this single metric.
How does Haemonetics' Days Payable compare to ITGR and IRTC?
According to the Medical Devices & Instruments industry distribution chart, Haemonetics ranks #623 out of 795 companies for Days Payable. This places Haemonetics in the lower half of its industry. The industry median Days Payable is 68.07. Haemonetics' value of 30.53 is 55.1% below this benchmark. Historically, Haemonetics' own Days Payable has ranged from 29.71 to 41.86 over the past decade. While the company's 10-year median is 39.88 vs. the industry median of 68.07, Haemonetics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Devices & Instruments company?
The median Days Payable among Medical Devices & Instruments companies is 68.07, based on 795 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Haemonetics's current Days Payable of 30.53 is 55.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Haemonetics and its competitors. For the Medical Devices & Instruments industry, the median Days Payable is 68.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Haemonetics's current Days Payable is 30.53, which is 23% below median its own 10-year median of 39.88. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Haemonetics stock overvalued right now?
Haemonetics (STU:HAZ) has a current Days Payable of 30.53. The stock's GF Value™ is €73.57, compared to a current price of €65.00 — trading 11.6% below its estimated fair value. The current Days Payable is 30.53, which is 23% below median its 10-year median of 39.88 and 55.1% below the Medical Devices & Instruments industry median of 68.07. Haemonetics' overall GF Score™ is 79/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Haemonetics (STU:HAZ), the current Days Payable is 30.53 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Haemonetics (STU:HAZ) Overvalued in 2026?
Based on GuruFocus' analysis, Haemonetics stock appears to be undervalued.
The current stock price of €65.00 is trading 11.6% below its estimated GF Value™ of €73.57.
Key valuation signals for STU:HAZ:
Days Payable: 30.53 (23% below median its 10-year median of 39.88)
GF Value™: €73.57 vs. price of €65.00 (11.6% below fair value)
Industry Position: 55.1% below the Medical Devices & Instruments median (#623 of 795)
No single metric tells the full story. See the STU:HAZ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company emphasizes its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.
79GF Score
Get the complete analysis for STU:HAZ
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:HAZ has been successfully added to your 
